Understanding the variant landscape, and genetic epidemiology of Multiple Endocrine Neoplasia in India.

IF 3 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Endocrine Pub Date : 2024-12-01 Epub Date: 2024-08-07 DOI:10.1007/s12020-024-03982-2
Aastha Vatsyayan, Mohamed Imran, Juhi Bhardwaj, Arvinden Vr, Srashti Jyoti Agrawal, Bhaskar Jyoti Saikia, Vigneshwar Senthivel, Kavita Pandhare, Rahul C Bhoyar, Mohit Kumar Divakar, Anushree Mishra, Bani Jolly, Suruchi Trehan, Sridhar Sivasubbu, Vinod Scaria
{"title":"Understanding the variant landscape, and genetic epidemiology of Multiple Endocrine Neoplasia in India.","authors":"Aastha Vatsyayan, Mohamed Imran, Juhi Bhardwaj, Arvinden Vr, Srashti Jyoti Agrawal, Bhaskar Jyoti Saikia, Vigneshwar Senthivel, Kavita Pandhare, Rahul C Bhoyar, Mohit Kumar Divakar, Anushree Mishra, Bani Jolly, Suruchi Trehan, Sridhar Sivasubbu, Vinod Scaria","doi":"10.1007/s12020-024-03982-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Multiple Endocrine Neoplasia (MEN) is a group of familial cancer syndromes that encompasses several types of endocrine tumors differentiated by genetic mutations in RET, MEN1 and CDKN1B genes. Accurate diagnosis of MEN subtypes can thus be performed through genetic testing. However, MEN variants remain largely understudied in Indian populations. Additionally, few dedicated resources to understand these disorders currently exist.</p><p><strong>Methods: </strong>Using the gold-standard ACMG/AMP guidelines, we systematically classified variants reported across the three genes in the IndiGen dataset, and established the genetic epidemiology of MEN in the Indian population. We further classified ClinVar and Mastermind variants and compiled all into a database. Finally, we designed a multiplex primer panel for rapid variant identification.</p><p><strong>Results: </strong>We have established the genetic prevalence of MEN as the following: 1 in 1026 individuals is likely to be afflicted with MEN linked with pathogenic RET mutations. We have further created the MAPVar database containing 3280 ACMG-classified variants freely accessible at: https://clingen.igib.res.in/MAPVar/ . Finally, our NGS primer panel covers 33 exonic regions across two pools through 38 amplicons with a total amplified region of 65 kb.</p><p><strong>Conclusion: </strong>Our work establishes that MEN is a prevalent disorder in India. The rare nature of Indian variants underscores the need of genomic and functional studies to establish a more comprehensive variant landscape. Additionally, our panel offers a means of cost-effective genetic testing, and the MAPVar database a ready reference to aid in a better understanding of variant pathogenicity in clinical as well as research settings.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"1178-1187"},"PeriodicalIF":3.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12020-024-03982-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/7 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Multiple Endocrine Neoplasia (MEN) is a group of familial cancer syndromes that encompasses several types of endocrine tumors differentiated by genetic mutations in RET, MEN1 and CDKN1B genes. Accurate diagnosis of MEN subtypes can thus be performed through genetic testing. However, MEN variants remain largely understudied in Indian populations. Additionally, few dedicated resources to understand these disorders currently exist.

Methods: Using the gold-standard ACMG/AMP guidelines, we systematically classified variants reported across the three genes in the IndiGen dataset, and established the genetic epidemiology of MEN in the Indian population. We further classified ClinVar and Mastermind variants and compiled all into a database. Finally, we designed a multiplex primer panel for rapid variant identification.

Results: We have established the genetic prevalence of MEN as the following: 1 in 1026 individuals is likely to be afflicted with MEN linked with pathogenic RET mutations. We have further created the MAPVar database containing 3280 ACMG-classified variants freely accessible at: https://clingen.igib.res.in/MAPVar/ . Finally, our NGS primer panel covers 33 exonic regions across two pools through 38 amplicons with a total amplified region of 65 kb.

Conclusion: Our work establishes that MEN is a prevalent disorder in India. The rare nature of Indian variants underscores the need of genomic and functional studies to establish a more comprehensive variant landscape. Additionally, our panel offers a means of cost-effective genetic testing, and the MAPVar database a ready reference to aid in a better understanding of variant pathogenicity in clinical as well as research settings.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
了解印度多发性内分泌肿瘤的变异情况和遗传流行病学。
目的:多发性内分泌肿瘤(MEN)是一组家族性癌症综合征,包括多种类型的内分泌肿瘤,根据 RET、MEN1 和 CDKN1B 基因的遗传突变进行区分。因此,可以通过基因检测对 MEN 亚型进行准确诊断。然而,在印度人群中,MEN 变异在很大程度上仍未得到充分研究。此外,目前了解这些疾病的专门资源很少:我们采用黄金标准 ACMG/AMP 指南,对 IndiGen 数据集中报告的三个基因的变异进行了系统分类,并确定了 MEN 在印度人群中的遗传流行病学。我们进一步对 ClinVar 和 Mastermind 变异进行了分类,并将所有变异编入数据库。最后,我们设计了一个多重引物面板,用于快速鉴定变异:结果:我们确定了 MEN 的遗传患病率如下:结果:我们将 MEN 的遗传患病率确定为:每 1026 人中就有 1 人可能患有与致病性 RET 突变有关的 MEN。我们进一步创建了 MAPVar 数据库,其中包含 3280 个 ACMG 分类变异,可免费访问:https://clingen.igib.res.in/MAPVar/ 。最后,我们的 NGS 引物面板通过 38 个扩增子覆盖了两个池中的 33 个外显子区域,扩增区域总长 65 kb:我们的工作证实了 MEN 是印度的一种常见疾病。印度变异的罕见性强调了基因组和功能研究的必要性,以建立更全面的变异情况。此外,我们的研究小组提供了一种具有成本效益的基因检测方法,而 MAPVar 数据库则提供了一种现成的参考,有助于在临床和研究环境中更好地了解变异的致病性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Endocrine
Endocrine ENDOCRINOLOGY & METABOLISM-
CiteScore
6.50
自引率
5.40%
发文量
295
审稿时长
1.5 months
期刊介绍: Well-established as a major journal in today’s rapidly advancing experimental and clinical research areas, Endocrine publishes original articles devoted to basic (including molecular, cellular and physiological studies), translational and clinical research in all the different fields of endocrinology and metabolism. Articles will be accepted based on peer-reviews, priority, and editorial decision. Invited reviews, mini-reviews and viewpoints on relevant pathophysiological and clinical topics, as well as Editorials on articles appearing in the Journal, are published. Unsolicited Editorials will be evaluated by the editorial team. Outcomes of scientific meetings, as well as guidelines and position statements, may be submitted. The Journal also considers special feature articles in the field of endocrine genetics and epigenetics, as well as articles devoted to novel methods and techniques in endocrinology. Endocrine covers controversial, clinical endocrine issues. Meta-analyses on endocrine and metabolic topics are also accepted. Descriptions of single clinical cases and/or small patients studies are not published unless of exceptional interest. However, reports of novel imaging studies and endocrine side effects in single patients may be considered. Research letters and letters to the editor related or unrelated to recently published articles can be submitted. Endocrine covers leading topics in endocrinology such as neuroendocrinology, pituitary and hypothalamic peptides, thyroid physiological and clinical aspects, bone and mineral metabolism and osteoporosis, obesity, lipid and energy metabolism and food intake control, insulin, Type 1 and Type 2 diabetes, hormones of male and female reproduction, adrenal diseases pediatric and geriatric endocrinology, endocrine hypertension and endocrine oncology.
期刊最新文献
Correction to: Therapeutic patient education and treatment intensification of diabetes and hypertension in subjects with newly diagnosed type 2 diabetes mellitus: a longitudinal study. Correction: Timing of the repeat thyroid fine-needle aspiration biopsy: does early repeat biopsy change the rate of nondiagnostic or atypia of undetermined significance cytology result? Hematological toxicities with Lutathera® for neuroendocrine neoplasms: post-marketing surveillance data from the US-FDA. SGLT2 inhibitors may reduce non-small cell lung cancer and not increase various neoplasms including several skin cancers. Clarification on the role of thyroid scintigraphy in the era of TIRADS: a response to Trimboli et al. (2024).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1